Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: A “central hub” in schizophrenia pathophysiology?

Steullet, P., Cabungcal, J.H., Monin, A., Dwir, D., O'Donnell, P., Cuenod, M., Do, K.Q.·2016·Schizophrenia Research
DOI 10.1016/j.schres.2014.06.021

Cited by (260)

Items 201–260 of 260

  1. Érosion prématurée des télomères et schizophrénies : synthèse et hypothèses
    Cécile Corfdir, Baptiste Pignon, Andreı̈ Szöke, Franck Schürhoff · 2021 · L Encéphale
  2. Restoring synaptic balance in schizophrenia: Insights from a thalamo-cortical conductance-based model
    Berndt, Lioba C S, Singh, Krish D, Shaw, Alexander D · 2026 · Schizophrenia Bulletin
  3. Changes in schizophrenia symptoms, tryptophan metabolism, neuroinflammation and the GABA-glutamate loop: A pilot study
    Estmia Van der Walt, Christiaan Beyers Brink, Esmé Jansen van Vuren · 2025 · South African Journal of Psychiatry
  4. Correlations between biochemical and clinical parameters in patients at risk for schizophrenia spectrum disorders
    Olga Konstantinovna Savushkina, И. С. Бокша, Maria A. Omelchenko, Е. Б. Терешкина, T. A. Prokhorova, E. A. Vorobyeva, Gulnur Sh. Burbaeva · 2023 · Vestnik nevrologii psihiatrii i nejrohirurgii (Bulletin of Neurology Psychiatry and Neurosurgery)
  5. Aging in Schizophrenia: Perspectives on Molecular Mechanisms and a Mini-review
    Akila Weerasekera, Öngür Dost, Du Fei · 2025 · Schizophrenia Bulletin
  6. Sodium benzoate treatment linked to increased glutathione levels and improved positive and negative symptoms, global function, and quality of life in patients with clozapine-resistant schizophrenia: secondary analysis of a randomized clinical trial
    Chieh‐Hsin Lin, Hsien‐Yuan Lane · 2025 · European Neuropsychopharmacology
  7. Alterations in lipid, redox, and energy metabolism in recent onset psychosis: a metabolomics study in non-smoking individuals and matched controls
    Daphne A M Dielemans, Arjen L. Sutterland, René Lutter, Michel van Weeghel, Arno R. Bourgonje, Hanno L. Tan, Harry van Goor, Anja Lok, Nico J.M. van Beveren, Lieuwe de Haan et al. · 2025 · Redox Biology
  8. Developmental Alterations in the Diffusion Tensor Imaging Analysis Along the Perivascular Space Index Suggest Possible Glymphatic-Related Mechanisms Underlying Excitation/Inhibition Imbalance and Psychosis Vulnerability in 22q11.2 Deletion Syndrome
    Alessandro Pascucci, Silas Forrer, Corrado Sandini, Valentina Mancini, Yasser Alemán‐Gómez, Stephan Eliez M. D, Farnaz Delavari · 2026 · Biological Psychiatry Global Open Science
  9. Apocynin-tandospirone derivatives demonstrate antioxidant properties in the animal model of schizophrenia
    Takashi Uehara, Masayoshi Kurachi, Takashi Kondo, Hitoshi Abe, Qing‐Li Zhao, Hiroko Itoh, Tomiki Sumiyoshi, Michio Suzuki · 2021 · Advances in Redox Research
  10. Causal relationship between genetically predicted mental disorders and frailty: a bidirectional and multivariable mendelian randomization study
    Wenxi Sun, Ping Sun, Sijia Tang, Xiaohui Wu, Jun Chen, Yiru Fang, Xiaobin Zhang · 2024 · BMC Psychiatry
  11. Apocynin-Tandospirone Derivatives Suppress Methamphetamine-Induced Hyperlocomotion in Rats with Neonatal Exposure to Dizocilpine
    Takashi Uehara, Masayoshi Kurachi, Takashi Kondo, Hitoshi Abe, Hiroko Itoh, Tomiki Sumiyoshi, Michio Suzuki · 2022 · Journal of Personalized Medicine
  12. Augmentation with glutamatergic modulators for schizophrenia: A network meta-analysis
    Chun-Wei Liang, Hsiao-Yi Cheng, Mei‐Chih Meg Tseng · 2025 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
  13. Microglia-derived metabolites as novel signaling molecules: regulating neural circuit function, behavior, and their role in psychiatric disorders
    Jiatai Li, Yonghou Zhao · 2026 · Frontiers in Cellular Neuroscience
  14. Differential effects of cariprazine, LY379268 and donepezil on EEG oscillations and auditory steady-state response in MK-801-treated rats: relevance for schizophrenia drug development
    Florian W. Adraoui, Maëlle Violas, Heloise HERBEL, Geoffrey Viardot, Kenza Hettak, Samuel Tugler, Morgane Chassignolle, Eric Delpy, Anne Maurin, Philippe L’Hostis et al. · 2026 · Neuropharmacology
  15. Redox Homeostasis and Oxidative Stress in Schizophrenia: Glutathione–NMDA–Neuroimmune Convergence and a Hypothesis-Generating Iron–Lipid Redox Extension
    Dusan Mihajlo Spasic, Snezana D. Spasić, Aleksandra Nikolić‐Kokić, Čedo Miljević · 2026 · International Journal of Molecular Sciences
  16. Nonpharmalogical Substances for Early Intervention
    Philippe Conus · 2016 · Key issues in mental health (Online)/Key issues in mental health (Print)
  17. ETHICAL APPROACH TO PREVENTION OF SCHIZOPHRENIA - CONCEPTS AND CHALLENGES
    Krešimir Radić, Marko Ćurković, Dario Bagarić, Maja Vilibić, Andrea Tomić, Maja Živković · 2018 · Psychiatria Danubina
  18. Electroencephalography and Schizophrenia
    Seung‐Hwan Lee · 2019 · 신경정신의학
  19. The effect of phencyclidine-mediated blockade of NMDA receptors in the early postnatal period on glutathione and sulfur amino acid levels in the rat brain as a potential causative factor of schizophrenia-like behavior in adulthood
    Elżbieta Lorenc‐Koci, Magdalena Górny, Grażyna Chwatko, Kinga Kamińska, Małgorzata Iciek, Zofia Rogóż · 2024 · Pharmacological Reports
  20. Curcumin as an Antioxidant Against Ziprasidone Induced Lipid Peroxidation in Human Plasma: Potential Relevance to Cortico Subcortical Circuit Function
    Anna Dietrich‐Muszalska, Piotr Kamiński, Bogdan Kontek, Edward Jacek Gorzelańczyk · 2025 · International Journal of Molecular Sciences
  21. O papel do sistema imune na neurogênese da esquizofrenia com enfoque na neuroinflamação/ The role of the immune system in the neurogenesis of schizophrenia with a focus on neuroinflammation
    Renato Lion Machado de Souza, Thais da Silva Raimundo, Michelangelo Juvelane · 2020 · Brazilian Journal of Health Review
  22. Pyramidal neurons
    Byron K.Y. Bitanihirwe, Tsung-Ung Wilson Woo · 2021 · Elsevier eBooks
  23. Developmental Glymphatic Dysfunction Underlies Excitation/Inhibition Imbalance and Psychosis Vulnerability in 22q11.2 Deletion Syndrome
    Alessandro Pascucci, Silas Forrer, Corrado Sandini, Valentina Mancini, Yasser Alemán‐Gómez, Stephan Eliez M. D, Farnaz Delavari · 2025 · medRxiv
  24. Anticorps anti-récepteur NMDA dans les premiers épisodes psychotiques
    Emmanuel Le Guen · 2014 · HAL
  25. Novel Treatments of Psychosis
    Walter Dunn, Stephen R. Marder · 2015 · Current Behavioral Neuroscience Reports
  26. Tratamento repetido com canabidiol atenua alterações comportamentais e moleculares em um modelo de esquizofrenia baseado no antagonismo dos receptores NMDA
    Felipe Villela Gomes · 2016
  27. Innate Immune Response and Psychotic Disorders
    Jaana Suvisaari, Outi Mantere · 2016 · Elsevier eBooks
  28. Effect of Phencyclidine on Neuregulin Expression, Cortical Interneurons, and Redox Dysregulation
    Nataša Petronijević, Nevena V. Radonjić · 2016 · Elsevier eBooks
  29. Article Open Access
    Holly Lawford‐Smith · 2015
  30. Complementary and Integrative Therapies for Older Age Bipolar Disorder
    Maria Cristina Poscablo-Stein, Adriana Patricia Hermida · 2017 · Springer eBooks
  31. SA21. Network Analysis of the SANS: Analysis of 3 Randomized Clinical Trials of Predominant Negative Symptoms
    Stephen Z. Levine, Stefan Leucht · 2017 · Schizophrenia Bulletin
  32. Year-end review in Schizophrenia Research 2017
    Urvakhsh Meherwan Mehta · 2018 · Schizophrenia Research
  33. S.03.02 Oxidative stress in schizophrenia pathogenesis
    K.Q. Do · 2019 · European Neuropsychopharmacology
  34. Excitotoxicity
    Yi Dong, Hong Lin, Amy Rattelle, Jessica A. Panzer, David R. Lynch · 2017 · Elsevier eBooks
  35. Inflammatory Response and Treatment-Resistant Mental Disorders: Should Immunotherapy Be Added to Pharmacotherapy?
    Barbara J. Limandri · 2020 · Journal of Psychosocial Nursing and Mental Health Services
  36. Magnetic Resonance Spectroscopy Studies in Schizophrenia
    Döst Öngür · 2020 · Springer eBooks
  37. Behavioural effects of cannabidiol in a preclinical model of neurodevelopmental disorders
    Tanzir Alam · 2018 · TSpace (University of Toronto)
  38. P.0768 Early intervention in schizophrenia: highlight of a specific time-window for the rescue of PVI maturation impairments through MMP9/RAGE pathway inhibition
    Daniella Dwir, Volker Mack, Enea Parietti, Marzieh Funk, Scott Hobson, Michel Cuénod, Cornelia Dorner‐Ciossek, K.Q. Do · 2021 · European Neuropsychopharmacology
  39. Pharmacological Targets and Mechanisms of Action of Antipsychotic Substances in the Context of the Neurochemical Theory of the Pathogenesis of Schizophrenia
    K. Yu. Kalitin, А. А. Спасов, Olga Yu. Mukha, Глеб Васильевич Придворов, В. А. Липатов · 2022 · Neuroscience and Behavioral Physiology
  40. Psychoneurobiology Research and Personalized Treatment of Schizophrenia
    Tomiki Sumiyoshi · 2022 · MDPI eBooks
  41. Prodromes and biological markers in schizophrenia: Importance for the dopamine, glutamate, and neurodevelopmental hypothesis
    Juan Pablo Díaz-Sánchez, Héctor Solís‐Chagoyán, Gloria Benítez‐King · 2022 · Salud Mental
  42. The effects of Memantine and MK801 on NMDA receptor switching 2B and 2A subunits in hippocampal cell culture.
    Ezequiel Uribe, Eduardo H. Sánchez-Mendoza · 2022 · Archivos de Neurociencias
  43. Кластеризация пациентов с клиническим риском шизофрении по биохимическим параметрам тромбоцитов для прогноза эффективности психофармакотерапии
    И. С. Бокша, Olga Konstantinovna Savushkina, Maria A. Omelchenko, T. A. Prokhorova, Е. Б. Терешкина, E. A. Vorobyeva, Gulnur Sh. Burbaeva · 2023 · Сибирский вестник психиатрии и наркологии
  44. Neuroimaging stratification reveals the striatal vulnerability to stress as a risk for schizophrenia
    Xiaoqian Ma, Nana Feng, Lena K. Palaniyappan, Luolong Cao, Zixin Gu, Jujiao Kang, Yuan Liu, Lijun Ouyang, Yujue Wang, Chunwang Li et al. · 2025 · Translational Psychiatry
  45. N-acetylcysteine: Impact on Psychiatric Disorders
    Sadia Binte Anwar Sonia, Muhammad Nurul Alam Siddiki, Sarmin Sultana, Iftekhar Hossain Chowdhury, Susmita Sinha, Miral Mehta, Mainul Haque · 2025 · Advances in Human Biology
  46. The Pathobiological Underpinnings of Psychosis: From the Stress-Related Hypothesis to a Multisystemic Approach
    Evangelos Karanikas · 2025 · NeuroSci
  47. Exposure to cigarette smoke during prenatal period alters the brain energy metabolism of rats subjected to an animal model of schizophrenia
    Wagner de Brito Veras, Gustavo Antunes Mastella, Patrícia Gomes Wessler, Lara Canever, Amanda Kunz Godói, Isabela Hubbe, Alander Michels, Patrícia Fernanda Schuck, João Pedro Veronezi Rohling, Emilio Luiz STRECK et al. · 2026 · Metabolic Brain Disease
  48. Childhood maltreatment and social cognition deficits across the psychosis spectrum: Evidence from the PREGAP study
    Borja Pedruzo, Clàudia Aymerich, Gonzalo Salazar de Pablo, José Manuel Rodríguez-Sánchez, Patxi Gil, Lander Madaria, Garazi Acasuso, Ainara Arnaiz, Ana González-Pinto, Daniel Alonso Alconada et al. · 2026 · Revista de Psiquiatría y Salud Mental
  49. Acute apocynin-tandospirone derivatives (ATDs) exacerbate methamphetamine-induced hyperlocomotion in rats
    Takashi Uehara, Hiroko Itoh, Hitoshi Abe, Yuzuru Kataoka, Takanori Senoo, Tatsuya Nagasawa, Michio Suzuki · 2026 · Psychopharmacology
  50. Myelin Matters in Schizophrenia : Neurobiological Insights from Rat Model and Human Studies
    Dorien A. Maas · 2019 · theses.fr (ABES)
  51. Glutathione deficiency in the early postnatal developmental period as a neurodevelopmental animal model of schizophrenia
    Zofia Rogóż, Agnieszka Wąsik · 2026 · Pharmacological Reports
  52. From brain bioenergetics to hypothalamic glucoregulation: A shared-systems hypothesis for intrinsic dysglycemia in schizophrenia
    Laurie Hamel, S x E rgio L. Pereira, Zeyu Yang, Ameth N. Garrido, Sri Mahavir Agarwal, Tony K.T. Lam, Margaret K. Hahn · 2026 · Reviews in Endocrine and Metabolic Disorders
  53. Decoding shared pathogenic networks of oxidative stress in neuropsychiatric disorders to prioritize multi-target therapeutics from natural products
    X J Xu, Zhu Ni, Yan-Bin Wang, Shasha Fan, Yanan Du, Xu Wang, Xiangyu Meng · 2026 · Cell Biology and Toxicology
  54. Evaluation of the antipsychotic and neuroprotective potential of berberine chloride hydrate in a preclinical psychosis model: Behavioural, biochemical, and histopathological evidence
    Uday Raj Sharma, G Shashikala, P.M. Manjunatha, Uday R, Yogendra Singh, Suresh Janadri, Surendra Vada, T. Haribabu · 2026 · Learning and Motivation
  55. Redox–Mitochondria–Immune Network Dysregulation in Schizophrenia: From Selective Cellular Vulnerability to Circuit Dysfunction
    Tingyan He, An Yu, Yulin Qian, Tonglin Wu, Changguo Ma · 2026 · Cells
  56. Insights into the blood–brain barrier in mental health disorders: from experimental models to clinical findings
    Maria Grazia Ferraro, Adrien Stanley, Pellegrino Lippiello, Silvia Pascarella, Luisa Speranza, Mariateresa Ricci, Floriana Volpicelli, Sergio Chieffi, Maria Concetta Miniaci · 2026 · Reviews in the Neurosciences
  57. Towards precision psychiatry: initial foundations and future directions
    Amit Etkin, Patricio O’Donnell, Kerry James Ressler, Husseini K. Manji · 2026 · Nature Reviews Drug Discovery
  58. Tryptophan Supplementation Reduces Schizophrenia-Like Symptoms in Apomorphine Treated Rats: Role of D2, GABA, and Glutamate Receptor Expression
    Shazia Nawaz, Sadia Basharat Ali, Rushda Afroz, Huma Ikram, Faisal Khan, Darakhshan Jabeen Haleem · 2026 · International Journal of Tryptophan Research
  59. N-Acetylcysteine in Schizophrenia: A Convergent Redox-Based Approach to Therapeutic Potential
    Enric Rubio-Contreras, Alonso Pérez‐Toribio, Patricia Alvaro, Ana M. Cosialls, Constanza Morén · 2026 · Antioxidants
  60. Molecular Crossroads: Exploring the Role of Oxidative Stress and Glutamate in Schizophrenia - A Pathway to Antioxidant Therapy
    Manvini. S, Pinki Verma · 2026 · Asian Journal of Research in Pharmaceutical Sciences